Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$81.5 million.

  • Beam Therapeutics' Cash from Operations rose 754.16% to -$81.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$338.2 million, marking a year-over-year decrease of 14901.18%. This contributed to the annual value of -$347.2 million for FY2024, which is 13274.64% down from last year.
  • Latest data reveals that Beam Therapeutics reported Cash from Operations of -$81.5 million as of Q3 2025, which was up 754.16% from -$76.4 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Cash from Operations registered a high of $218.5 million during Q1 2022, and its lowest value of -$109.8 million during Q1 2023.
  • Over the past 5 years, Beam Therapeutics' median Cash from Operations value was -$76.4 million (recorded in 2024), while the average stood at -$42.2 million.
  • Examining YoY changes over the last 5 years, Beam Therapeutics' Cash from Operations showed a top increase of 66635.91% in 2022 and a maximum decrease of 388092.9% in 2022.
  • Over the past 5 years, Beam Therapeutics' Cash from Operations (Quarter) stood at $1.8 million in 2021, then crashed by 3880.93% to -$69.2 million in 2022, then surged by 295.22% to $135.1 million in 2023, then plummeted by 156.54% to -$76.4 million in 2024, then fell by 6.7% to -$81.5 million in 2025.
  • Its Cash from Operations was -$81.5 million in Q3 2025, compared to -$76.4 million in Q2 2025 and -$103.9 million in Q1 2025.